Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
A notice of allowance for a MicroBiome Therapeutics LLC patent application covering the use of glyceollin for treatment of diabetes and obesity was recently issued by the US Patent and Trademark Office, according to a company press release. An allowance notice signifies that a patent application has survived the opposition period before finalization.
The treatment of metabolic disorders using glyceollins as well as a potential role in modulating the gastrointestinal microbiome is being investigated by MicroBiome Therapeutics.
Animal studies have revealed that glyceollins show activity in some human disease models, including breast and ovarian cancer, hypercholesterolemia and metabolic disorders. According to the release, glyceollin I, II and III are natural products made by soy plants that can help fight infectious organisms and other stressors.
http://www.healio.com/endocrinology...ed-for-glyceollin-as-diabetes-obesity-therapy
The treatment of metabolic disorders using glyceollins as well as a potential role in modulating the gastrointestinal microbiome is being investigated by MicroBiome Therapeutics.
Animal studies have revealed that glyceollins show activity in some human disease models, including breast and ovarian cancer, hypercholesterolemia and metabolic disorders. According to the release, glyceollin I, II and III are natural products made by soy plants that can help fight infectious organisms and other stressors.
http://www.healio.com/endocrinology...ed-for-glyceollin-as-diabetes-obesity-therapy